REGENXBIO Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
Other than as set forth as follows, during the three months ended June 30, 2026, none of our directors or Section 16 reporting officers adopted or terminated a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (Rule 10b5-1 Plan) or that constituted a “non-Rule 10b5-1 trading arrangement,” as such term is defined in Item 408(a) of the SEC’s Regulation S-K:
| Rule 10b5-1 Trading Plan · Aggregate # of | ||||||
|---|---|---|---|---|---|---|
| Provides for · Securities to be | ||||||
| Name | Title | Action | Date Adopted | Expiration Date | Purchase/Sale | Purchased/Sold |
| David C. Stump | Director | Adoption of Rule 10b5-1 Plan | 6/18/2026 | 5/25/2028 | Sale | 25,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.